Drug-eluting Balloon Catheters Market – By Product, By Material, By End Use – Global Forecast, 2025 to 2034

Drug-eluting Balloon Catheters Market Size

The global drug-eluting balloon catheters market size was valued at USD 637.8 million in 2024 and is expected to exhibit growth at a CAGR of 9.9% from 2025 to 2034. High market growth can be attributed to the growing prevalence of peripheral and cardiovascular diseases, an increasing preference for minimally invasive procedures, and a rising geriatric population, among other contributing factors.
 

The incidence of cardiovascular diseases (CVDs), including coronary artery disease, strokes, and peripheral artery disease (PAD), has surged globally due to risk factors such as aging, unhealthy lifestyles, and the prevalence of conditions like diabetes and hypertension. For instance, according to the Centers for Disease Control and Prevention (CDC), cardiovascular diseases remain the leading cause of death globally, with an estimated 19 million deaths in 2021.
 

In the U.S. alone, heart disease accounted for 702,880 deaths in 2022, which is about one in every five deaths. This rising incidence has intensified the demand for minimally invasive treatments, where drug-eluting balloon (DEB) catheters have a distinct advantage in reducing arterial blockages and improving blood flow without leaving a permanent implant. DEBs are particularly effective in treating complex lesions where traditional stents may be less effective, further driving their adoption.
 

Drug-eluting balloon catheters, also known as drug-coated balloons, aid in treating hyperplasia. The catheter carries an antiproliferative drug, usually paclitaxel or sirolimus, which is delivered to the arterial walls as the balloon expands. Additionally, it offers controlled drug delivery to treat cardiovascular or peripheral diseases.
 

Drug-eluting Balloon Catheters Market Trends

Innovations in drug delivery mechanisms, catheter design, and material composition have enhanced the effectiveness of DEB catheters in treating vascular blockages, particularly for patients with peripheral artery disease (PAD) and coronary artery disease (CAD). These advancements are garnering interest from healthcare providers seeking more effective, minimally invasive solutions, thereby expanding the use of DEB catheters within the medical community.
 

• One of the most significant advancements has been in the drug coatings applied to DEB catheters. Newer drug formulations, such as paclitaxel and sirolimus-based coatings, enable more efficient and targeted drug delivery to arterial walls, minimizing systemic exposure and reducing the risk of adverse effects. Innovations in drug-coating technology ensure that therapeutic agents are delivered precisely to the blockage site, thereby improving outcomes by lowering restenosis rates and enhancing long-term arterial patency. These developments have established DEB catheters as a reliable choice for patients with complex vascular conditions.
   
• Furthermore, modern DEB catheter designs focus on precision and flexibility, facilitating easier navigation through complex vascular anatomies. With improved maneuverability and a reduced catheter diameter, these devices can be used in narrower and more intricate blood vessels, extending their application to previously challenging cases. This refined design has also made DEB catheters more accessible for patients with complicated vascular blockages, enabling successful treatment in scenarios that might not have been possible with older technology.
   

Drug-eluting Balloon Catheters Market Analysis

Based on product, the market is classified into coronary artery disease drug-eluting balloon catheters and peripheral vascular disease drug-eluting balloon catheters. The peripheral vascular disease drug-eluting balloon catheters segment generated the highest revenue of USD 353 million in 2024.
 

• Peripheral vascular disease drug-eluting balloons are particularly effective in treating complex lesions, such as long or diffuse blockages, where traditional stents may be less effective or unsuitable. By releasing therapeutic agents that reduce smooth muscle cell proliferation and prevent restenosis, DEB catheters for PVD help maintain blood flow and improve outcomes. This effectiveness in complex cases has led to the strong adoption of DEB catheters in the peripheral vascular disease segment, contributing significantly to its market share.
   
• Healthcare providers increasingly prefer minimally invasive procedures for PVD due to reduced recovery times, lower complication rates, and enhanced patient comfort. Drug-eluting balloon catheters, which provide both physical expansion and localized drug delivery without leaving behind a permanent implant, align well with these treatment goals. This approach has driven the widespread acceptance of DEB catheters for PVD, supporting the segment’s leading market position.
   

Based on material, the drug-eluting balloon catheters market is classified into polyurethane, nylon, and other materials. The polyurethane segment accounted for USD 225.4 million in market revenue in 2024 and is anticipated to grow at a CAGR of 10.4% between the 2025 to 2034.
 

• Polyurethane is a versatile, biocompatible material known for its flexibility, durability, and resistance to abrasion, making it an ideal choice for manufacturing DEB catheters. Its superior elasticity and softness allow for precise navigation through complex vascular structures, reducing patient discomfort and minimizing the risk of vascular injury during procedures. These attributes make polyurethane-based catheters the preferred choice in a variety of vascular interventions, ranging from peripheral to coronary applications.
   
• Furthermore, polyurethane’s durability and abrasion resistance are crucial for DEB catheters, which must maintain structural integrity while delivering drugs to vascular walls. These catheters often navigate narrow and intricate pathways in the body, making them susceptible to surface wear. Polyurethane’s ability to withstand abrasion ensures the catheter's longevity and reliability, allowing it to perform effectively even in challenging anatomical regions and during multiple uses.
   

Based on end use, the drug-eluting balloon catheters market is segmented into hospitals and clinics, ambulatory surgical centers, and catheterization laboratories. The hospitals and clinics segment dominated the market in 2024 and is anticipated to reach USD 938.3 million by the end of the forecast period.
 

• This high market share is attributed to the increasing prevalence of chronic ailments that require surgical interventions, the rising incidence of peripheral and cardiovascular diseases, and the subsequent number of hospital admissions. Peripheral artery disorders are among the major conditions influencing hospital admissions for catheterization procedures among adults. For instance, according to a report published by Frontiers on Cardiovascular Epidemiology and Prevention in 2022, over 238 million people worldwide suffered from peripheral artery disease, contributing to a significant number of deaths globally.
   
• This high prevalence has led to the increased adoption of drug-eluting balloon catheters in hospitals and clinics. The growing demand for minimally invasive surgical interventions, improved surgical care, and catheterization procedures, along with the availability of highly skilled healthcare professionals, are additional factors positively driving the market growth of the hospitals and clinics segment.
   

North America drug-eluting balloon catheters market accounted for USD 272.2 million in market revenue in 2024 and is anticipated to grow at a CAGR of 8.4% between the 2025 to 2034.
 

• North America holds a significant share of the global drug-eluting balloon (DEB) catheters market, largely due to its advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and strong support for minimally invasive procedures. The U.S. experiences a high incidence of peripheral artery disease (PAD) and coronary artery disease (CAD), which drives demand for innovative treatment options like DEB catheters.
   
• Healthcare providers in North America have adopted DEB technology because it offers effective drug delivery with fewer complications compared to traditional stents. Additionally, extensive clinical studies conducted in the region have validated the efficacy of DEB catheters, bolstering their acceptance among interventional cardiologists and vascular specialists.
   

France drug-eluting balloon catheters market is projected to grow remarkably in the coming years.
 

• French healthcare authorities prioritize minimally invasive treatments, and DEB catheters provide a compelling solution for treating complex vascular blockages, particularly in cases where stents are not ideal.
   
• Increased funding for cardiovascular treatment and research in France has further contributed to the development and adoption of DEB technology. With a well-developed healthcare system and growing awareness among healthcare providers, France is a major player in the European DEB catheters market.
   

Japan holds a dominant position in the Asia Pacific drug-eluting balloon catheters market.
 

• With one of the highest proportions of elderly individuals worldwide, Japan faces a significant burden of peripheral and coronary artery diseases. DEB catheters offer a minimally invasive treatment that is particularly well-suited for older adults, who may face higher risks from traditional surgical options.
   
• Japanese healthcare providers have increasingly adopted DEB technology, and the Japanese government’s emphasis on quality healthcare access and advanced treatments further promotes the market’s growth. Japan’s support for medical device innovation also facilitates faster regulatory approvals, helping DEB catheters achieve strong market traction.
   

Drug-eluting Balloon Catheters Market Share

The market is competitive, with a mix of large multinationals like B. Braun, Becton, Dickinson and Company, and Boston Scientific Corporation leading in innovation and extensive product portfolios. Regional companies and new entrants, particularly from Asia Pacific, are also making significant strides. The market is characterized by frequent technological advancements, such as improved vaccine efficacy, enhanced safety profiles, and better storage and distribution methods, which drive ongoing product development. Strategic partnerships, mergers, and acquisitions are common as companies seek to expand market reach and enhance their technological capabilities.
 

Drug-eluting Balloon Catheters Market Companies

Prominent players operating in the drug-eluting balloon catheters industry include:

• Aachen Resonance GmbH
• B. Braun
• Becton, Dickinson and Company
• Biosensors International
• Biotronik AG
• Boston Scientific Corporation
• Eurocor GmbH
• iVascular S.L.U.
• Lepu Medical Technology (Beijing) Co. Ltd.
• MedAlliance
• Medtronic plc
• Zhejiang Barty Medical Technology Co.Ltd
   

Drug-eluting Balloon Catheters Industry News:

• In February 2022, Boston Scientific Corporation acquired Baylis Medical Company Inc. which provides transseptal access solutions, guidewires, sheaths, and balloon dilators that support catheter-based left-heart procedures. This acquisition helped the company expand its geographical presence along with the business revenue by entering new markets.
   
• In March 2021, B. Braun Interventional Systems Inc. (BIS), an affiliate of B. Braun Medical Inc., collaborated with Infraredx, a Nipro Company, to conduct a clinical trial for the B. Braun SeQuent Please ReX Drug-Coated PTCA Balloon Catheter. This collaboration enabled the company to receive U.S. Food and Drug Administration (FDA) approval. It also facilitated the development of long-term global cooperation between the B. Braun Group of Companies and Japan-based Nipro Corporation to advance coronary artery disease management.
   

The drug-eluting balloon catheters market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Coronary artery disease drug-eluting balloon catheters
  • Paclitaxel
  • Sirolimus
• Peripheral vascular disease drug-eluting balloon catheters
  • Paclitaxel
  • Sirolimus

Market, By Material

• Polyurethane
• Nylon
• Other materials

Market, By End Use

• Hospitals and clinics
• Ambulatory surgical centers
• Catheterization laboratories

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE